Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Racial and Ethnic Disparities and Health Inequities in Oncology Care

Premiere Date: Wednesday, August 24, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. Psychological (apa)
  6. Dentists (ADA CERP)
  7. PA (aapa)
  8. Dietetic Registration (CDR)
  9. Social work (ASWB)
  10. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Sunday, August 24, 2025

Faculty


Edith Peterson Mitchell, MD, MACP, FCPP, FRCPEdith Peterson Mitchell, MD, MACP, FCPP, FRCP (Moderator)
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
Philadelphia, PA
116th President of the National Medical Association

Ajay K. Nooka, MD, MPH, FACPAjay K. Nooka, MD, MPH, FACP 
Associate Professor, Department of Hematology and Medical Oncology
Medical Director, Winship Data and Technology Applications Shared Resource
Winship Cancer Institute, Emory University School of Medicine
Atlanta, GA

Yaw A. Nyame, MD, MS, MBAYaw A. Nyame, MD, MS, MBA 
(he/him/his)
Assistant Professor, Department of Urology
University of Washington
Associate Director, Center for Urologic Research and Education
Program Lead for Black/African American Populations
Office of Community Outreach and Engagement
Fred Hutchinson Cancer Center
Seattle, WA

Ana I. Velázquez Mañana, MD, MScAna I. Velázquez Mañana, MD, MSc 
(she/her/ella)
Assistant Professor, Division of Hematology/Oncology
Assistant Director of Diversity, Equity, Inclusion and Accessibility
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA

Statement of Need

There are many factors that lead to health care disparities in oncology care and outcomes for racial and ethnic populations, including root causes such as structural racism, social determinants of health (SDoH), and geographic location. As with other areas of health care, individuals with low income, low health literacy, transportation barriers, or lack of health insurance or paid leave are far less likely to be screened for cancer or managed according to guideline-directed treatment. Thus, underserved patient populations are more likely to be diagnosed with late-stage cancers, leading to worse outcomes and higher mortality. Furthermore, individuals of racial and ethnic groups seeking or receiving oncology care are disproportionately impacted by unconscious and conscious bias, which exacerbates poorer outcomes.

While oncology treatments continue to advance in the era of modern medicine, the healthcare system remains plagued by longstanding health inequities. It is imperative that all members of the health care team recognize their important roles in providing education, services, and equitable care for all patients. In this live CME Outfitters webcast, expert faculty will discuss the impact of unconscious and systemic biases, SDoH, and regional, racial, and ethnic disparities and provide tools and resources to improve oncology care for all patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Analyze ethnic and regional disparities resulting in health inequities in oncology care.
  • Improve recognition of multiple myeloma, melanoma, prostate, and lung cancers.
  • Analyze the influence of SDoH in cancer care in order to improve equity and accessibility to cancer treatments and outcomes.

Financial Support

Supported by an educational grant provided by the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.

Target Audience

Physicians, PAs, nurse practitioners, nurses/nurse navigators, pharmacists, psychologists, dietitians, social workers, and other professionals specializing in diagnosing or treating patients with cancer

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning formats:
Live Activity

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

IPCE Credit(TM):This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Mitchell reports the following financial relationships:

Advisory Board: Corvus Pharmaceuticals, Inc.

Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.

Dr. Nooka reports the following financial relationships:

Advisory Board Adaptive Biotechnologies; Amgen Inc.; BeyondSpring Inc.; Bristol Myers Squibb Company; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Oncopeptides, Inc.; Pfizer Inc.; Sanofi; Secura Bio, Inc.; and Takeda Pharmaceuticals U.S.A., Inc..

Grant/Research Support (to Emory University): Amgen Inc.; Arch Oncology; Bristol Myers Squibb Company; Genentech, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Kite; Merck & Co., Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Grant/Research Support (for investigator-initiated studies): Amgen Inc.; GSK; Janssen Pharmaceuticals, Inc.; Merck; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Nyame reports the following financial relationships:

Research Consultant: Ortho Clinical Diagnostics

Dr. Velázquez Mañana reports the following financial relationships:

Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.

Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology

The following peer reviewer and CME Outfitters staff have no financial relationships:
  • Jeffrey Helfand, DO (peer reviewer)
  • Meghann Taft-Lockard (planning committee)
  • Kashemi Rorie, PhD (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

    WC-053-082422-57

    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download